EQUUS TOTAL RETURN, INC.
No SEC Form 4 filings for $EQS in the last 30 days.
See all $EQS insider activity →Equus Total Return (EQS) received a notice from the NYSE on October 6, 2026, for non-compliance with listing rules due to its stock price being below $1.00 for 30 consecutive days. The company has six months to regain compliance, with options including a reverse stock split, and trading continues during this period.
EQUUS TOTAL RETURN, INC. (EQS) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Contact: Equus Total Return, Inc. 1-888-323-4533 EQUUS RECEIVES NOTICE OF NON-COMPLIANCE WITH NEW YORK STOCK EXCHANGE SHARE PRICE RULE Company Intends to Regain Compliance with NYSE Rule Notice Has No Immediate Impact on the Listing or Trading of Equus Common Stock H
Equasens (EQS) reported H1 2026 revenue of €124.5m, up 7.3% reported basis, and ARR of €111.1m (+8.8% vs. 30 June 2025). Maintenance and subscriptions rose to €55.7m (+8.4%), and software and services to €21.7m (+24.9%). Growth was driven by PHARMAGEST and AXIGATE LINK integrations, with MEDICAL SOLUTIONS benefiting from EREVO.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning EQS (EQUUS TOTAL RETURN, INC.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 4 bearish.
Recent EQS coverage spans financial news, corporate actions and regulation.
Risk of a near-term corporate action (reverse split) increases, which can pressure the stock and raise liquidity/delisting concerns even without an immediate delisting.
Near-term risk is continued NYSE deficiency status and market overhang until the company cures the $1.00 average-price requirement; reverse split is a stated alternative.
H1 growth and ARR expansion suggest improving recurring revenue momentum, with upside tied to Ségur Wave 2 and integrated acquisitions.
The filing confirms shareholder voting outcomes (board nominees elected; say-on-pay approved), but provides no new financial guidance or corporate action beyond governance results.
The upcoming 2026 annual meeting and proposed governance decisions are unlikely to cause significant short-term price movements but could influence long-term investor confidence.
AlphAI scores every news story that mentions EQS with an AI model for sentiment and relevance, and aggregates insider trades from EQUUS TOTAL RETURN, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Equus Total Return (EQS) received a notice from the NYSE on October 6, 2026, for non-compliance with listing rules due to its stock price being below $1.00 for 30 consecutive days. The company has six months to regain compliance, with options including a reverse stock split, and trading continues during this period.
3 min readEQUUS TOTAL RETURN, INC. (EQS) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Contact: Equus Total Return, Inc. 1-888-323-4533 EQUUS RECEIVES NOTICE OF NON-COMPLIANCE WITH NEW YORK STOCK EXCHANGE SHARE PRICE RULE Company Intends to Regain Compliance with NYSE Rule Notice Has No Immediate Impact on the Listing or Trading of Equus Common Stock H
3 min readEquasens (EQS) reported H1 2026 revenue of €124.5m, up 7.3% reported basis, and ARR of €111.1m (+8.8% vs. 30 June 2025). Maintenance and subscriptions rose to €55.7m (+8.4%), and software and services to €21.7m (+24.9%). Growth was driven by PHARMAGEST and AXIGATE LINK integrations, with MEDICAL SOLUTIONS benefiting from EREVO.
4 min readEQUUS TOTAL RETURN, INC. (EQS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 1 f8k_equus722026.htm FORM 8-K ___________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest e
2 min readEquus Total Return, Inc. (EQS) has announced its 2026 annual stockholder meeting on June 30, 2026, where stockholders will vote on the election of five directors and a non-binding advisory proposal for 2025 executive compensation. Key executive compensation figures for 2025 were detailed, including CEO John A. Hardy receiving $896,943 and the CEO pay ratio being approximately 2.42 times that of the median employee. The Board recommends voting "For" all director nominees and the say-on-pay proposal.
3 min readThis article provides an analysis of Equus Total Return, Inc.'s (EQS) leadership and management team. It highlights CEO John Hardy's compensation and ownership, along with the average tenure of both management and the board. The article also includes a timeline of recent management and company updates and an overview of CEO compensation relative to company earnings.
4 min readHOUSTON, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Equus Total Return, Inc. ( NYSE: EQS ) ( "Equus" or the "Company" ) reports net assets as of September 30, 2025, of $26.5 million. Net asset value per share decreased to $1.90 as of September 30, 2025, from $2.51 as of June 30, 2025.
2 min readEQS Post-admission Duties announcement: EVOTEC SE / Completion of Share Repurchase Programme / Announcement pursuant to Article 5 ( 1 ) ( b ) , ( 3 ) of Regulation ( EU ) No. 596/2014 in conjunction with Article 2 ( 2 ) and ( 3 ) of Delegated Regulation ( EU ) 2016/1052
3 min readEQS-News: Eleving Group increases 2025/2030 bond issue offering amount to up to EUR 300 million due to strong investor demand ...
2 min readEQS-News: The Platform Group AG / Key word ( s ) : Bond The Platform Group AG taps up 2024 corporate bond Düsseldorf, 1 September 2025.
2 min read
